Tildrakizumab not checked
Sun Pharma · SCH 900222 · MK-3222
FollowEvery change as it happens, and a Monday email
Trials
6 active
11 in total · 7 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter”In the company’s words, NCT06611163 on ClinicalTrials.gov
- Tested for
- Active Psoriatic Arthritis, Moderate to Severe Genital Psoriasis, Psoriatic Arthritis, Moderate-to-severe Chronic Plaque Psoriasis
- Main trialPhase 3
- “This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .”In the company’s words, NCT04314531 on ClinicalTrials.gov
- Other names
- SCH 900222 · MK-3222 · TILD · TILD sub-cutaneous
Other drugs for Active Psoriatic Arthritis
- SHR0302Hengrui · Phase 3
- SonelokimabMoonLake Immunotherapeutics AG · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- ZasocitinibTakeda · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
Coming up1
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 4 Jun 2025 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | |
| Phase 3Active, not recruiting | 21 Jan 2026 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. | |
| Phase 3Active, not recruiting | Dec 2028 | Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | |
| Phase 2/3Active, not recruiting | 7 Apr 2025 | A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis | |
| Phase 3Completed | 28 Sep 2015 | A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) | |
| Phase 3Completed | 28 Oct 2015 | A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) | |
| Phase 3Withdrawn | Aug 2018 | A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) | |
| Phase 3Completed | 5 Apr 2024 | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | |
| Phase 3Completed | 26 Mar 2025 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | |
| Phase 2Authorised | not given | Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU) | |
| Phase 2Authorised | not given | Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026